Akumentis Healthcare launches synthetic CBD for epilepsy
时间:2024-06-02 02:42:37 阅读(143)
Akumentis Healthcare Limited on Thursday announced that it has launched Clasepi. According to the company’s press statement, Clasepi, DCGI-approved prescription cannabidiol (CBD) is specifically formulated to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older.
Clasepi marks a development as the first synthetic CBD product of its kind to be made available in India, it claimed. The product with THC content below 0.1%, stands out for its non-psychotropic nature.
“Patients grappling with a rare and severe form of epilepsy often endure a protracted journey to obtain an accurate diagnosis, tolerating nearly five years of uncontrolled seizures from the onset. In certain instances, individuals may enter adulthood without a precise diagnosis, despite wrestling with conditions like LGS, DS, or TSC.. We understand the immense physical and emotional toll that frequent seizures can have on patients and their families. This is the driving force behindour commitment to developing novel solutions that effectively relieves the complexities of these disorders,” Kanishk Jain, Executive Director,Akumentis said.
According to the World Health Organisation (WHO), epilepsy constitutes a considerable portion of the global disease burden, affecting approximately 50 million people worldwide, with 20% of patients residing in India.
WHO asserts that up to 70% of individuals with epilepsy could achieve seizure freedom with the proper use of progressive anti seizure medicines. Beyond theseizures themselves, pervasive myths and discrimination surrounding epilepsy create additional hurdles for affected individuals and their families. In India, a sizable number of patients suffers from Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) for whom doctors will find clasepi as a new armamentarium in epilepsy therapy protocol.
Clasepi comes with important usage considerations; it is not recommended for individuals allergic to cannabidiol or any of its ingredients. Akumentis stresses the significance of adhering to healthcare providers’ prescription guidance for optimal use and safe consumption, it added.
上一篇:Paytm share price rises 7% in 6 months, may rally this much more; JP Morgan bullish, should you buy-
下一篇:Yen falls to the lowest level in seven months; Rupee remains resilient
猜你喜欢
- F&O expiry 29 Sep- Nifty may fall to 16500 below 17000; Track India Cement, Sun Pharma, Lupin stocks for gains
- Market volatility, regulatory diktats play part- New client additions by brokers see marked decline
- Edelweiss arm aims to raise USD 1 billion in third distressed asset fund
- Making of India’s Maharatna PSUs- The journey of these government companies to becoming crown jewels
- Manufacturing PMI falls to 18-month low in December
- Equity mutual fund inflows at Rs 15,890 crore in April, SIP contribution dips
- Oil slips as China COVID curbs outweigh concerns over US output
- Market short-term texture mildly overbought; stick to level-based trading; Adani Ports among stocks to buy
- PE & VC exits declined by 56% in 2022 due to market uncertainty